The five pillars of cancer care currently comprise surgery, radiotherapy, traditional chemotherapy, precision therapy, and immunotherapy. Each of these treatments addresses cancer in different ways, targeting the malignancy itself. However, the link between obesity and cancer has been well established, and obesity has been recognized as a risk factor for certain types of cancer. Given the strong correlation between obesity and cancer risk, including potential molecular mechanisms that may foster cancer growth, an emphasis on weight management could represent a profound shift in cancer prevention and treatment.
The integration of obesity management into the treatment paradigm could involve a multidisciplinary approach, incorporating dietary interventions, physical activity, behavioral changes, and potentially even novel pharmacological agents aimed at curbing weight gain. By addressing obesity as a modifiable risk factor, healthcare professionals may be able to not only treat cancer more effectively but also prevent it in certain instances. The introduction of weight management as another pillar in cancer care would require rigorous scientific research and clinical trials. However, if successfully implemented, it could revolutionize the way we approach cancer treatment and prevention, placing a strong emphasis on the patient’s overall well-being and lifestyle choices, and ushering in a new era of holistic cancer care.
It is the purpose of this website to draw attention to this unmet need in medicine and to address some of the questions that surround this new medical field.
AI Generated Summary Podcast (8:02)
NCI Obesity Fact Sheet
Obesity is a major health concern that is not only associated with chronic diseases like cardiovascular disease, but it is also linked with an increased risk of cancer. According to the National Institutes of Health (NIH), 4-8% of all cancers can be attributed to obesity. The underlying mechanism of obesity causing cancer is complex, and researchers are still trying to gain a better understanding of it. However, researchers know that certain lifestyle changes can help reduce the risk of developing cancer due to obesity. In particular, diet, exercise, and behavior therapy are the mainstay of intervention to fight against obesity and, thereby, lower the risk of cancer. For more information, please click on the link to the research paper cited and also check out the NIH’s National Cancer Institute infographic on the cancers associated with overweight and obesity.
AI Generated Summary Podcast (9:48)
This webpage from the Centers for Disease Control and Prevention (CDC) explores the strong link between obesity and cancer risk. It outlines how being overweight or obese increases the likelihood of developing 13 specific types of cancer, which account for 40% of all cancer diagnoses in the United States. The article also discusses how excess weight can lead to bodily changes, such as inflammation and hormone imbalances, which contribute to cancer development. Finally, the CDC provides practical steps for individuals and healthcare providers to reduce the risk of obesity-related cancers, emphasizing the importance of healthy lifestyle choices and preventative measures.
AI Generated Summary Podcast (7:06)
Summary
The World Health Organization (WHO) has released a report on the growing epidemic of obesity in Europe and Central Asia. The report reveals that obesity is a major cause of preventable death and disability, linked to 13 types of cancer, and is expected to surpass smoking as the leading preventable cancer risk factor in some countries. The report emphasizes that obesity is a complex condition that requires multidisciplinary treatment and management, and urges the implementation of comprehensive policy interventions, such as restricting unhealthy food marketing to children, taxing sugar-sweetened beverages, and improving health systems to address obesity management.
AI Generated Summary Podcast (18:57)
Summary
This Cancer Research UK excerpt details the strong link between obesity and cancer risk in adults. Obesity is identified as the second leading cause of cancer in the UK, increasing the likelihood of developing 13 specific cancer types. The text explains how excess fat influences growth hormones, inflammation, and sex hormones, thereby promoting cellular division and cancer development. Methods for assessing healthy weight, such as BMI and waist-to-height ratio, are discussed, along with advice on maintaining a healthy weight to reduce cancer risk. Importantly, the text clarifies that obesity does not cause cancer in children.
AI Generated Summary Podcast (13:24)
Summary
This paper proposes a new model of obesity that combines the obesogens model (OBS) and the oxidation-reduction model (REDOX). The OBS model posits that environmental chemicals can disrupt hormonal signaling and lead to adiposity, while the REDOX model suggests that reactive oxygen species (ROS) generated by these chemicals can alter metabolic signaling, increasing insulin secretion and disrupting energy efficiency. The authors argue that this OBS/REDOX model can explain the data supporting both the energy balance model (EBM) and the carbohydrate-insulin model (CIM), which are the two most prevalent models of obesity. They propose that obesogens act by interfering with hormone receptors and hijacking redox signaling pathways, ultimately leading to inappropriate and false signals about energy status, resulting in weight gain.
AI Generated Summary Podcast (10:11)
This research paper investigates the “obesogenic memory” – the persistent cellular and epigenetic changes in adipose tissue after weight loss. Using single-nucleus RNA sequencing and multi-omics analysis in both humans and mice, the study demonstrates that significant transcriptional and epigenetic alterations remain in adipocytes even after substantial weight loss. These persistent changes, primarily driven by epigenetic modifications at enhancers and promoters, prime cells for pathological responses, potentially explaining the common “yo-yo” effect of weight regain. The findings suggest that targeting these epigenetic changes could improve long-term weight management.
AI Generated Summary Podcast (17:39)
This research paper details the Breast Cancer Weight Loss (BWEL) trial, a large-scale, randomized controlled trial investigating whether weight loss interventions can improve outcomes for overweight or obese women with breast cancer. The study uses a two-year, telephone-based lifestyle intervention incorporating dietary modifications, increased physical activity, and behavioral strategies, drawing upon elements from successful prior trials like the Diabetes Prevention Program and Look AHEAD. The intervention’s primary goal is a 10% weight loss, delivered via 42 coaching sessions, with flexibility to meet diverse participant needs. Researchers aim to determine if weight loss impacts invasive disease-free survival and overall survival, potentially influencing future breast cancer treatment.
AI Generated Summary Podcast (15:09)
The connection between a new class of weight loss drugs and cancer risk reduction – MSKCC
Memorial Sloan Kettering Cancer Center shared a post on X:
“In this episode of Cancer Straight Talk, Diane Reidy-Lagunes sits down with MSK’s Neil Iyengar to discuss the intriguing connection between a new class of weight loss drugs, called GLP-1 agonists, and cancer risk reduction.
The Battle of the Incretins is ON!
AI GENERATED SUMMARY PODCAST (13:12)
The Link Between Obesity and Cancer provides a comprehensive and up-to-date review of the relationship between obesity and cancer. It opens with a global perspective on obesity and cancer incidence, followed by in-depth discussions on cancers for which we have sufficient and new evidence of a causal relationship with obesity. Readers will gain fundamental knowledge about which different cancer types are related to obesity and why. The book provides a significant knowledge base for clinicians to know when to act, along with specific management guidelines for patients with obesity as well as how to understand the potential risk factors and how to directly or indirectly minimize these risks. The book also provides scientific data for any researcher in the field, identifying the molecular mechanisms and links behind the development of malignancy and promoting research on new affective target pathways m developing therapeutic strategies.
Key Features
• Provides essential knowledge on how to understand the link between obesity and cancer and why and how this occurs; enables readers to gain fundamental knowledge on which cancer types are related to obesity and why
• Provides a significent knowledge base for clinicians on when to act, along with patient management guidelines for patients with obesity as well as how to understand potential risk factors and how to minimize them
• Contains new scientific data and findings for researchers, which identify the molecular mechanisms and links behind the development of malignancy
The book, The Link Between Obesity and Cancer on sale at Amazon or at ScienceDirect®.
AI GEnerated Summary PoDcast (22:40)
AI Generated Summary Podcast (7:52)
Ozempic, Wegovy covered by Medicare and Medicaid under Biden admin proposal for anti-obesity GLP-1 drugs
The Biden administration is looking to expand access to anti-obesity GLP-1 drugs like Ozempic and Wegovy for people who have Medicare and Medicaid.
Biden wants to expand access to Ozempic and other popular weight loss drugs
President Joe Biden is trying to expand access to pricey blockbuster drugs in his final months in office.Read more…
Younger Breast Cancer Patients Face Higher Recurrence Risk
A retrospective study found that younger patients with ER-positive, ERBB2-negative breast cancer are more prone to late distant recurrence. Medscape Medical News
GLP-1 RA Drugs Benefit People With SLE, Lupus Nephritis
The glucose-lowering and weight-reducing drug class appears to benefit the heart and kidneys in people with lupus and lupus nephritis, independently of glucose-lowering and weight loss. Medscape Medical News
The Scan by 2 Minute Medicine®: Versatile Ozempic, Healthcare Reform, Unlocking the Brain, and Chickens and the Next Pandemic:
The Scan by 2 Minute Medicine® is a pop-culture medical newsletter and exclusive benefit for 2 Minute Medicine Plus subscribers. We begin with a discussion about Ozempic’s potential in treating alcohol use disorder. Then we
Biden wants drugs like Wegovy, Ozempic covered by Medicare, Medicaid
Millions of Americans would be eligible to have popular weight-loss drugs like Wegovy or Ozempic covered by Medicare and Medicaid under a rule the Biden administration has proposed.
Medicare moves to expand coverage for weight-loss drugs Wegovy, Zepbound
The Biden administration is proposing a major expansion of how Medicare and Medicaid cover the weight-loss drugs Wegovy and Zepbound.
Inside the telehealth-fueled GLP-1 alternative market
How does the market for compounded GLP-1 drugs work? Let us explain.